The Prostate Cancer Charity comments on the launch of new drug,
abiraterone, which has now been licensed for use in the UK, and can
be prescribed by doctors to help extend the lives of men with
advanced prostate cancer, which has stopped responding to existing
treatments, by an average of four months.